Which of the following drugs acts by inhibiting the late sodium current in the heart?

Explanation

## Correct Answer: D. Ranolazine Ranolazine is a selective inhibitor of the **late inward sodium current** (late INa) in cardiac myocytes. Unlike traditional antianginal agents that reduce myocardial oxygen demand by lowering heart rate or contractility, ranolazine works through a unique mechanism: it blocks the persistent (late) phase of the L-type sodium channel, which normally closes within milliseconds after depolarization. In ischemic conditions, this late sodium current becomes pathologically prolonged, leading to intracellular sodium accumulation, which triggers reverse-mode Na+/Ca2+ exchanger activity, causing calcium overload and diastolic dysfunction. By inhibiting this late INa, ranolazine reduces intracellular calcium overload without affecting heart rate, blood pressure, or coronary blood flow—making it a pure metabolic modulator. This mechanism is distinct from beta-blockers, calcium channel blockers, or nitrates. Ranolazine is particularly useful in chronic stable angina, especially in Indian patients with diabetes-associated angina, as it improves diastolic function and exercise tolerance without hemodynamic compromise. It is approved as an add-on therapy in patients inadequately controlled on conventional antianginal drugs per Indian cardiology guidelines. ## Why the other options are wrong **A. Trimetazidine** — Trimetazidine inhibits **mitochondrial fatty acid oxidation** (specifically the last step via inhibition of 3-ketoacyl-CoA thiolase), not sodium current. It shifts myocardial metabolism from fatty acid to glucose oxidation, improving ATP production during ischemia. While it is also a metabolic modulator used in angina, its mechanism is entirely different from ranolazine's sodium channel inhibition. This is a common NBE trap—both are non-hemodynamic antianginals, but students must distinguish their molecular targets. **B. Ivabradine** — Ivabradine selectively inhibits the **If current (funny current)** in the sinoatrial node, reducing heart rate without affecting contractility or blood pressure. It is used in chronic stable angina and heart failure with reduced ejection fraction. The trap here is confusing 'current inhibition' with 'sodium current inhibition'—ivabradine blocks a hyperpolarization-activated cyclic nucleotide-gated channel current, not INa. This is mechanistically distinct from ranolazine. **C. Fasudil** — Fasudil is a **Rho kinase inhibitor** used primarily in cerebral vasospasm (post-subarachnoid hemorrhage) and pulmonary hypertension. It works by inhibiting the Rho/ROCK pathway, leading to vasodilation and improved endothelial function. It has no direct effect on cardiac sodium currents. This option tests whether students confuse vasodilator mechanisms with electrophysiological ion channel effects—a common distractor in pharmacology. ## High-Yield Facts - **Late INa inhibition** is the unique mechanism of ranolazine—blocks the persistent sodium current phase, not the fast inward current like Class I antiarrhythmics. - **Ranolazine does NOT reduce heart rate, blood pressure, or coronary blood flow**—it is a pure metabolic modulator, making it safe in patients with bradycardia or hypotension. - **Trimetazidine inhibits fatty acid oxidation** (3-ketoacyl-CoA thiolase), while **ivabradine inhibits If current**—both are non-hemodynamic antianginals but mechanistically distinct from ranolazine. - **Intracellular calcium overload** in ischemia is driven by reverse-mode Na+/Ca2+ exchanger activity secondary to late INa-induced sodium accumulation—ranolazine breaks this cycle. - **Ranolazine is approved for chronic stable angina** in India as add-on therapy, particularly beneficial in diabetic patients with diastolic dysfunction. ## Mnemonics **RANA for Ranolazine** **R**everse Na+/Ca2+ exchanger (blocks late INa → ↓ Na+ → ↓ reverse exchanger activity) | **A**dd-on antianginal | **N**o heart rate/BP change | **A**cts on late sodium current. Use this when distinguishing ranolazine from other metabolic modulators. **Late INa = Ranolazine; If = Ivabradine; FAO = Trimetazidine** Quick 3-way discriminator: **Late INa** (persistent sodium) → Ranolazine | **If** (funny current, SA node) → Ivabradine | **FAO** (fatty acid oxidation) → Trimetazidine. Memorize these three distinct mechanisms to avoid confusion on exam day. ## NBE Trap NBE pairs ranolazine with other 'non-hemodynamic antianginals' (trimetazidine, ivabradine) to trap students who know these drugs reduce angina but confuse their mechanisms. The key discriminator is **late INa inhibition**—only ranolazine blocks this specific current; the others work via metabolism or heart rate reduction. ## Clinical Pearl In Indian clinical practice, ranolazine is increasingly used in diabetic patients with chronic stable angina who remain symptomatic despite beta-blockers and calcium channel blockers, because it improves diastolic function without causing hypotension or bradycardia—a critical advantage in elderly patients with comorbid hypertension or heart failure. _Reference: KD Tripathi Pharmacology Ch. 31 (Antianginal Drugs); Harrison's Principles of Internal Medicine Ch. 243 (Ischemic Heart Disease)_